Inflammatory bowel disease patients experiencing a loss of response to infliximab regain long-term response after undergoing granulocyte/monocyte apheresis: A case series.

Yoko Yokoyama ¹, Koji Kamikozuru ², Kenji Watanabe ², Shiro Nakamura ² , Cytokine. 2018 Mar;103:25-28.

To our best knowledge, this is the first report of adding a non-drug GMA to restore the efficacy of infliximab. The outcomes, albeit in three cases, are relevant in therapeutic settings and should inspire further studies in a larger number of patients.

https://pubmed.ncbi.nlm.nih.gov/29291447/